| id | Study | Lib. in paper | Exposition period | Study type |
Control type |
Tags | OR 95%CI | x1/n1 x0/n0 | no cases | no exposed | ROB | Ref. | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| S4995 R13093 |
Drechsel, 2020 | Neonatal infection (follow up 6 months of age) | 1st trimester | prospective cohort | unexposed, sick | Adjustment: No | 0.94 [0.04;20.73] C | 0/14 2/66 | 2 | 14 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S4952 R12992 |
Moens (Controls exposed to Vedolizumab), 2020 | Infections during the first year of life | at least 1st trimester | retrospective cohort | exposed to other treatment, sick excluded | Adjustment: No |
2.37 [0.59;9.61] C excluded (control group) |
7/67 3/64 | 10 | 67 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S4951 R12987 |
Moens (Controls unexposed, sick), 2020 | Infections during the first year of life | at least 1st trimester | retrospective cohort | unexposed, sick | Adjustment: No | 0.87 [0.29;2.63] C | 7/67 7/59 | 14 | 67 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S3072 R4709 |
Duricova, 2019 | Infection complications (within 1 year of life) | during pregnancy (anytime or not specified) | retrospective cohort | unexposed, disease free | Adjustment: Yes | 0.86 [0.32;2.32] | -/72 -/69 | - | 72 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S3123 R8744 |
De Lima, 2018 | Number of infections treated with systemic antibiotics | during pregnancy (anytime or not specified) | prospective cohort | exposed to other treatment, sick | Adjustment: No | 1.09 [0.19;6.20] C | 4/15 3/12 | 7 | 15 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S3093 R4777 |
Luu, 2018 | All infections children (0-1 year) | 3rd trimester | retrospective cohort (claims database) | exposed to other treatment, sick | 3rd trimester exposure Adjustment: Yes | 0.89 [0.76;1.05] | -/716 -/4,444 | - | 716 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S3076 R4723 |
Vinet (Controls unexposed, disease free), 2018 | Serious infections in the offspring (≥1 hospitalization with infection within the first 12 months of life) | during pregnancy (anytime or not specified) | retrospective cohort | unexposed, disease free excluded | Adjustment: Yes |
1.70 [0.80;3.70] excluded (control group) |
12/380 279/14,596 | 291 | 380 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S3077 R4727 |
Vinet (Controls unexposed, sick), 2018 | Serious infections in the offspring (≥1 hospitalization with infection within the first 12 months of life) | 3rd trimester | retrospective cohort | unexposed, sick | Adjustment: Yes | 1.40 [0.50;3.60] | 5/156 49/2,476 | 54 | 156 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S3070 R4693 |
De Lima (Controls unexposed, disease free), 2016 | Infections requiring antibiotics (in the first year of life) | during pregnancy (anytime or not specified) | prospective cohort | unexposed, disease free excluded | Adjustment: No |
0.47 [0.24;0.89] C excluded (control group) |
13/55 183/459 | 196 | 55 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S3071 R4702 |
De Lima (Treatment stopped during pregnancy, sick), 2016 | Infections requiring antibiotics (in the first year of life) | 1st and 2nd trimester | prospective cohort | unexposed, sick | Adjustment: No | 0.65 [0.21;2.04] C | 7/24 12/31 | 19 | 24 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| S3037 R4574 |
Seirafi, 2014 | Infections in newborn (up to week 8 post-partum) | 3 months (or more) before pregnancy or during pregnancy excluded | retrospective cohort | unexposed, sick | Adjustment: No before conception and/or during pregnancy |
1.53 [0.14;17.19] C excluded (exposition period) |
2/118 1/90 | 3 | 118 |
|
ref | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total | 7 studies | 0.90 [0.77;1.04] | 96 | 1,064 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1: Controls unexposed, sick; 2: Controls unexposed, sick; 3: Treatment stopped during pregnancy, sick;
Asymetry test p-value = 0.7021 (by Egger's regression)
slope=-0.1231 (0.0478); intercept=0.0934 (0.2304); t=0.4052; p=0.7021
excluded 3070, 3076, 4952